The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease

Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease

May 18, 2018 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Another concern is a reluctance to expose those with autoimmune disease to ICIs. In this cohort, 94% of patients received immunotherapy for their cancers only after failing conventional chemotherapy regimens. This suggests that RD may be a factor in delaying immunotherapy treatments.

You Might Also Like
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Explore This Issue
May 2018
Also By This Author
  • RheumPAC Supports Rheumatology Through the Pandemic

There is also worry about the generalizability of the results due to the advanced stages of cancer that were seen before immunotherapy was instituted. This may be another indication of delay because ICI treatments are being used more often as first-line agents for many advanced malignancies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Further Research

Further research is needed. Dr. Thanarajasingam is following patients with preexisting RD and those who develop it following exposure to the inhibitors. She would like to know if there is any impact on the response of their cancer. There is also a need to answer questions about how to intervene during a flare to minimize the impact on cancer treatment.

“Because ICIs have shown such dramatic responses in advanced cancer, their use has been expanding to many different forms of cancer,” says Dr. Thanarajasingam. “I want physicians to not immediately exclude their RD patients from eligibility just because they have existing autoimmune disease. This study would support using immunotherapy in a select group who can be followed closely by both oncology and rheumatology.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Kurt Ullman has been a freelance writer for more than 30 years and a contributing writer to The Rheumatologist for 10 years.

Reference

  1. Richter MD, Pinkston O, Kottschade LA, et al. Brief report: Cancer immunotherapy in patients with preexisting rheumatic disease: The Mayo Clinic experience. Arthritis Rheumatol. 2018 Mar;70(3):356–360.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: immune checkpoint inhibitor (ICI)Issue: May 2018

You Might Also Like:
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)